21.99 USD
↘ 1.38 (5.91%)LIVE (AS OF 03:03 PM EDT)
Alumis Inc. Common Stock
ALMSNASDAQ • USD
Market: OPEN
Open?$23.28
High?$23.87
Low?$21.63
Prev. Close?$23.37
Volume?994.2K
Avg. Volume?1.6M
VWAP?$22.18
Rel. Volume?0.62x
Bid / Ask
Bid?$21.95 × 100
Ask?$21.99 × 100
Spread?$0.04
Midpoint?$21.97
Valuation & Ratios
Market Cap?3.0B
Shares Out?123.1M
Float?71.1M
Float %?57.7%
P/E Ratio?N/A
P/B Ratio?9.87
EPS?-$1.91
Dividend?0.00%
Ex-Dividend?N/A
Technical Outlook
Loading...
Fundamental Outlook
Loading...
Short Interest
Loading...
Financial Health
Current Ratio?4.34Strong
Quick Ratio?4.34Strong
Cash Ratio?1.22Strong
Debt/Equity?0.00Low
ValuationRICHLY VALUED
Score50/100
P/E?N/A▾
P/B?9.87HIGH▾
P/S?123.60HIGH▾
P/FCF?N/A▾
EV/EBITDA?-6.4CHEAP▾
EV/Sales?119.87HIGH▾
Returns & Efficiency
ROE?-80.8%WEAK▾
ROA?-59.1%WEAK▾
Cash Flow & Enterprise
FCF?$-370176000
Enterprise Value?$2.9B
Related Companies
Loading...
News
Profile
Alumis Inc is a clinical-stage biopharmaceutical company with an initial focus on developing its two Tyrosine Kinase 2 ("TYK2") inhibitors: envudeucitinib ("envu"), an allosteric TYK2 inhibitor for the treatment of PsO and SLE; and A-005, a central nervous system ("CNS") penetrant allosteric TYK2 inhibitor, to offer the therapeutic benefit of TYK2 inhibition within the CNS for a broad range of neuroinflammatory and neurodegenerative diseases.
Address
280 EAST GRAND AVENUE
SOUTH SAN FRANCISCO, CA 94080
Phone: 650-231-6625
SOUTH SAN FRANCISCO, CA 94080
Phone: 650-231-6625